Oral antibiotic therapyStandard IV antibiotic therapy
Oral antibiotic therapy: Participants randomised to the experimental arm will switch to oral antibiotic therapy as soon as possible after clinical stability and within 4 days after initiation of effective IV antibiotic therapy. Children who have not received antibiotics, or who have received oral antibiotics before the blood culture becomes positive, may also be randomised; thus, prior IV therapy is not required in the experimental arm.
Standard IV antibiotic therapy: Participants allocated to the control group will continue IV therapy for at least 5 days after initiation of effective IV antibiotic therapy, with 7 days recommended, followed by oral step-down if appropriate.
Study summary
This nationwide, multicenter, randomized, non-inferiority trial of children and adolescents with uncomplicated bloodstream infections aims to investigate if early-oral antibiotic switch (experimental arm) is non-inferior to standard intravenous antibiotics (control arm) with respect to treatment failure.
Eligibility
Sex
ALL
Min age
4 Weeks
Max age
17 Years
Healthy volunteers
No
INCLUSION CRITERIA
1. Age 4 weeks to 17 years
2. Positive blood culture with a i) pathogenic bacterium (eg, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacterales, Fusobacterium spp. and other pathogenic bacteria) or ii) preliminary blood culture result (eg, Gram-negative rods or Gram-positive cocci in clusters/chains) judged by the investigator to be clinically relevant (ie, not a contaminant) and for which IV antibiotic therapy would be indicated according to standard guidelines
3. Clinical stability, defined as: (a) respiratory and haemodynamic stability, without need for oxygen, IV fluid therapy or inotropic support; and (b) well-appearing with signs of clinical improvement (eg, improved physical activity), as judged by the investigator
4. Tolerating oral fluids and diet, as judged by the investigator
5. Within the randomization window (see below)
6. Informed consent obtained from a parent or guardian, and from the patient if aged 15 years or older
Randomization window:
Randomization will take place (1) as soon as possible after eligibility is confirmed, and (2) before completion of a maximum of 4 days (96 hours) of effective IV antibiotic therapy, including the duration of the last IV dose (eg, 8 hours for penicillin and 24 hours for ceftriaxone)
EXCLUSION CRITERIA
1. Complicated infections: a. Suspicion of endocarditis (echocardiography not performed routinely), b. Suspicion of CNS infection or post-septal cellulitis, c. Foreign material (eg, bone infection involving prosthetic material). d. Complicated postoperative course (eg, perforated appendicitis)
2. Blood culture positive with a. Neisseria meningitidis, b. Streptococcus pneumoniae if afebrile within 24 hours of blood culture collection, c. bacteria considered possible contaminants (eg, coagulase-negative staphylococci, Corynebacterium spp., Micrococcus spp.)
3. Premature infants with a corrected age of less than 28 days
4. No available suitable oral antibiotic (eg, due to antimicrobial resistance or contraindications)
5. Known chronic disease associated with an increased risk of severe infection: i) Immunosuppression, e.g., chemotherapy or biological therapy predisposing to severe infections, ii) Permanent central venous catheter due to an underlying condition, iii) Severe urinary tract abnormalities predisposing to bacteremia, including children receiving prophylactic antibiotic treatment.
Primary outcome measure(s)
Number of Participants with Treatment Failure — Within 8 weeks of randomization Treatment failure, defined as clinically and/or microbiologically confirmed disease progression or relapse, adjudicated by an independent, blinded adjudication committee.
Trial sites (18)
Facility
City
Region
Status
Department of Pediatrics, Aabenraa Hospital
Aabenraa
Denmark
Department of Pediatrics, Aalborg University Hospital
Aalborg
Denmark
Aarhus University Hospital
Aarhus
Denmark
Copenhagen University Hospital, Rigshospitalet
Copenhagen
Denmark
Department of Pediatrics, Esbjerg Hospital
Esbjerg
Denmark
Department of Paediatrics and adolescent medicine, NIDO Danmark, Gødstrup Hospital
Gødstrup
Denmark
Department of Pediatrics, Herlev Hospital
Herlev
Denmark
Department of Pediatrics, Hillerød Hospital
Hillerød
Denmark
Department of Pediatrics, Hjørring Hospital
Hjørring
Denmark
Department of Pediatrics, Holbæk Hospital
Holbæk
Denmark
Department of Pediatrics, Hvidovre Hospital
Hvidovre
Denmark
Department of Pediatrics, Kolding Hospital
Kolding
Denmark
Department of Pediatrics, Nykøbing Falster Hospital
Nykøbing Falster
Denmark
Hans Christian Andersen Children's Hospital, Odense University Hospital
Odense
Denmark
Department of Pediatrics, Randers Hospital
Randers
Denmark
Department of Pediatrics, Roskilde University Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.